The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
用户_3gesBYkXd2E
1个月前
134
10
已关闭
DOI:
文献链接:
其他信息:
NC Bodick, WW Offen, HE Shannon…
Alzheimer disease …, 1997
psycnet.apa.org
Assessed the therapeutic effects of selective cholinergic replacement using oral xanomeline, an ml/m4 receptor agonist, in a multicenter study of 343 patients, aged 60–90 yrs, with Alzheimer's disease (AD). Ss were randomized to parallel treatment arms (placebo, 25, 50, and 75 mg oral xanomeline) and followed through 6 mo of double-blind therapy and 1 mo of single-blind placebo washout. Completer analysis, using the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog), revealed a significant treatment effect …
